Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.
P & T : a peer-reviewed journal for formulary management(2018)
摘要
Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要